Catabasis Pharmaceuticals Inc (NASDAQ:CATB)’s Stock Is Sell After More Market Selling

April 20, 2018 - By Henry Gaston

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Logo

The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) registered an increase of 86.35% in short interest. CATB’s total short interest was 401,400 shares in April as published by FINRA. Its up 86.35% from 215,400 shares, reported previously. With 393,400 shares average volume, it will take short sellers 1 days to cover their CATB’s short positions. The short interest to Catabasis Pharmaceuticals Inc’s float is 2.33%.

The stock decreased 4.97% or $0.09 during the last trading session, reaching $1.72. About 241,506 shares traded. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has risen 19.23% since April 20, 2017 and is uptrending. It has outperformed by 7.68% the S&P500.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $49.94 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Coverage

Among 2 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catabasis Pharmaceuticals had 2 analyst reports since November 20, 2017 according to SRatingsIntel. Wedbush maintained the shares of CATB in report on Tuesday, March 20 with “Outperform” rating. The rating was upgraded by Citigroup to “Buy” on Monday, November 20.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: